Core Viewpoint - The approval of the first Aβ-PET imaging agent in China marks a significant breakthrough in the early diagnosis of Alzheimer's disease (AD), potentially advancing diagnosis by 15-20 years [1][2]. Company Overview - Meizhong Jiahe Medical Technology Development Group is a leader in high-end medical imaging diagnostics in China, with its Shanghai Meizhong Jiahe Medical Imaging Diagnosis Center playing a crucial role in the high-end medical market in Shanghai [2][3]. - The center is equipped with advanced imaging technologies, including GE Signa PET/MR, PET/CT, and others, providing diagnostic services to multiple medical institutions in the region [3]. Industry Impact - The introduction of the Aβ-PET imaging agent is expected to enhance the professional image of Meizhong Jiahe in the medical imaging sector and facilitate collaborations with top medical institutions and research teams [2]. - The center's innovative business model, which combines independent third-party services with shared imaging resources and remote diagnostics, demonstrates significant growth potential in the medical imaging service market [3]. Technological Innovation - The center has developed an AI-assisted diagnostic evaluation system in collaboration with Hexin Health, which screens critical health indicators and generates comprehensive reports, significantly reducing the risk of missed diagnoses [4]. - The ongoing demand for precision medicine is likely to further solidify the center's leading position in the high-end imaging service market [4].